Cardio Diagnostics (CDIO) Competitors $3.82 +0.14 (+3.80%) As of 07/3/2025 03:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CDIO vs. ENLV, GBIO, TPST, DARE, SNYR, CARA, PASG, CVKD, TENX, and CYTHShould you be buying Cardio Diagnostics stock or one of its competitors? The main competitors of Cardio Diagnostics include Enlivex Therapeutics (ENLV), Generation Bio (GBIO), Tempest Therapeutics (TPST), Dare Bioscience (DARE), Synergy CHC (SNYR), Cara Therapeutics (CARA), Passage Bio (PASG), Cadrenal Therapeutics (CVKD), Tenax Therapeutics (TENX), and Cyclo Therapeutics (CYTH). These companies are all part of the "pharmaceutical products" industry. Cardio Diagnostics vs. Its Competitors Enlivex Therapeutics Generation Bio Tempest Therapeutics Dare Bioscience Synergy CHC Cara Therapeutics Passage Bio Cadrenal Therapeutics Tenax Therapeutics Cyclo Therapeutics Cardio Diagnostics (NASDAQ:CDIO) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation. Is CDIO or ENLV more profitable? Enlivex Therapeutics has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -28,539.39%. Enlivex Therapeutics' return on equity of -57.67% beat Cardio Diagnostics' return on equity.Company Net Margins Return on Equity Return on Assets Cardio Diagnostics-28,539.39% -84.55% -74.63% Enlivex Therapeutics N/A -57.67%-50.52% Which has more risk & volatility, CDIO or ENLV? Cardio Diagnostics has a beta of 2.96, suggesting that its stock price is 196% more volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Do insiders & institutionals believe in CDIO or ENLV? 8.1% of Cardio Diagnostics shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 22.3% of Cardio Diagnostics shares are held by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has higher earnings & valuation, CDIO or ENLV? Cardio Diagnostics has higher revenue and earnings than Enlivex Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCardio Diagnostics$40K166.17-$8.38MN/AN/AEnlivex TherapeuticsN/AN/A-$15.01M-$0.66-1.78 Do analysts rate CDIO or ENLV? Cardio Diagnostics currently has a consensus target price of $60.00, indicating a potential upside of 1,470.68%. Enlivex Therapeutics has a consensus target price of $10.00, indicating a potential upside of 751.06%. Given Cardio Diagnostics' higher possible upside, analysts plainly believe Cardio Diagnostics is more favorable than Enlivex Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardio Diagnostics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Does the media prefer CDIO or ENLV? In the previous week, Cardio Diagnostics' average media sentiment score of 0.00 equaled Enlivex Therapeutics'average media sentiment score. Company Overall Sentiment Cardio Diagnostics Neutral Enlivex Therapeutics Neutral SummaryCardio Diagnostics and Enlivex Therapeutics tied by winning 6 of the 12 factors compared between the two stocks. Get Cardio Diagnostics News Delivered to You Automatically Sign up to receive the latest news and ratings for CDIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CDIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDIO vs. The Competition Export to ExcelMetricCardio DiagnosticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.40M$2.91B$5.53B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E RatioN/A21.5627.4020.24Price / Sales166.17281.35419.60118.25Price / CashN/A41.9536.6357.47Price / Book0.547.518.085.67Net Income-$8.38M-$55.05M$3.16B$248.47M7 Day Performance5.82%4.71%2.84%3.32%1 Month Performance-23.45%4.89%3.69%5.20%1 Year Performance-76.42%5.82%35.30%21.35% Cardio Diagnostics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDIOCardio Diagnostics2.7187 of 5 stars$3.82+3.8%$60.00+1,470.7%-76.7%$6.40M$40K0.001ENLVEnlivex Therapeutics3.2023 of 5 stars$1.16+6.4%$10.00+762.1%-11.7%$25.78MN/A-1.7670GBIOGeneration Bio3.0064 of 5 stars$0.36-5.3%$7.33+1,937.6%-85.7%$25.47M$24.56M-0.33150TPSTTempest Therapeutics1.8005 of 5 stars$6.85+1.0%$30.00+338.0%-74.0%$24.97MN/A-0.3820DAREDare Bioscience1.761 of 5 stars$2.56-9.2%$12.00+368.8%-22.3%$24.96M$10K-15.0630News CoverageGap DownHigh Trading VolumeSNYRSynergy CHC3.7667 of 5 stars$2.57-3.0%$10.00+289.1%N/A$24.36M$34.83M0.0040CARACara Therapeutics0.372 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580News CoverageGap DownHigh Trading VolumePASGPassage Bio2.8958 of 5 stars$0.33-14.4%$7.50+2,140.1%-48.3%$24.30MN/A-0.33130Gap UpCVKDCadrenal Therapeutics3.0342 of 5 stars$11.44-7.4%$32.00+179.7%N/A$24.29MN/A-1.244Gap DownTENXTenax Therapeutics1.311 of 5 stars$5.62-2.9%$17.50+211.4%+87.4%$24.02MN/A-2.279CYTHCyclo TherapeuticsN/A$0.72flat$0.95+31.8%N/A$23.72M$870.73K-0.809 Related Companies and Tools Related Companies ENLV Competitors GBIO Competitors TPST Competitors DARE Competitors SNYR Competitors CARA Competitors PASG Competitors CVKD Competitors TENX Competitors CYTH Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CDIO) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardio Diagnostics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardio Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
